Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.94 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.89 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.89 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.89 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.89 |
| ▸ | STK10 | O94804 | 1/20 | 0.89 |
| ▸ | ABL1 | P00519 | 1/20 | 0.89 |
| ▸ | INSR | P06213 | 1/20 | 0.89 |
| ▸ | RET | P07949 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.89 |
| ▸ | SRC | P12931 | 1/20 | 0.89 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.89 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.89 |
| ▸ | CDK2 | P24941 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900585 | 0.97 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29464189 | 0.94 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29351024 | 0.94 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL16766960 | 0.94 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL8100 | 0.94 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4924110 | 0.93 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL574229 | 0.93 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232064 | 0.93 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3637153 | 0.93 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232460 | 0.93 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846787-A1 | NOVEL COMPOSITION OF LAPATINIB OF ORAL SOLID DOSAGE FORM AND METHOD OF MANUFACTURING THEREOF | BDR Pharmaceuticals International Private Limited (IN) | 2021-07-14 | — | — | EP | disclosed |
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9023354-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO, JOSEPH P. | 2015-04-16 | — | — | US | disclosed |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2596366-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012012653-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO JOSEPH P (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | EGFR 2/4885ERBB2 4/4885ABCB11 3953/4885 |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | EGFR 2/4885ERBB2 4/4885ABCB11 3953/4885 |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | EGFR 2/4885ERBB2 4/4885ABCB11 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.